Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

NCT06217302 is registered in ClinicalTrials.gov with Alessandro Doria as lead sponsor.

NCT NCT06217302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06217302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease
Lead sponsor
Alessandro Doria
Phase
Phase 3
Overall status
Recruiting
Start date
October 31, 2024
Completion date
May 31, 2029
Enrollment
150 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 1, diabetic nephropathies, heart failure, kidney failure, chronic